AHA: CMS proposal for drug ad transparency ‘important first step’

The AHA voiced support for a Centers for Medicare & Medicaid Services’ proposal to require drug pricing transparency in direct-to-consumer television advertisements and encouraged the agency to “rein in skyrocketing drug prices” for patients and the providers who serve them. “We appreciate CMS’s focus on this issue, and we believe this proposal represents an important first step in bringing more transparency to drug pricing,”

Related Resources

AHA letter to Ways and Means Committee on the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113.
AHA Center for Health Innovation Market Scan
A recent report in MobiHealth News explores how well-funded, established startups and fledgling companies alike are finding ways to cut the costs of…
Advancing Health Podcast
Civica Rx is the brainchild of hospitals and health systems that formed a collaborative to hold down the spiraling costs of essential generic drugs. How is the…
The American Hospital Association (AHA), the Federation of American Hospitals (FAH), and the American Society of Health-System Pharmacists (ASHP) released a…